A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
In today’s clinical practice, the treatment of type 2 diabetes mellitus should be targeted not only at achieving glycemic control, but should also affect other modified risk factors for cardiovascular disease including hypertension, overweight, frequent hypoglycemia, etc. [4] Empagliflozin is the fi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2017-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1747 |
| _version_ | 1827961706456809472 |
|---|---|
| author | M. V. Amosova V. V. Fadeev |
| author_facet | M. V. Amosova V. V. Fadeev |
| author_sort | M. V. Amosova |
| collection | DOAJ |
| description | In today’s clinical practice, the treatment of type 2 diabetes mellitus should be targeted not only at achieving glycemic control, but should also affect other modified risk factors for cardiovascular disease including hypertension, overweight, frequent hypoglycemia, etc. [4] Empagliflozin is the first antidiabetic drug with the new approved indication allowing it to be used for the reduction of cardiovascular mortality risks in patients with type 2 diabetes and comorbid cardiovascular diseases. |
| first_indexed | 2024-04-09T16:30:51Z |
| format | Article |
| id | doaj.art-8233cb8f1c7345b795aa457a1183ed2a |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:30:51Z |
| publishDate | 2017-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-8233cb8f1c7345b795aa457a1183ed2a2023-04-23T06:57:06ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902017-12-0103384310.21518/2079-701X-2017-3-38-431729A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETESM. V. Amosova0V. V. Fadeev1First Moscow State Medical University named after I.M. SechenovFirst Moscow State Medical University named after I.M. SechenovIn today’s clinical practice, the treatment of type 2 diabetes mellitus should be targeted not only at achieving glycemic control, but should also affect other modified risk factors for cardiovascular disease including hypertension, overweight, frequent hypoglycemia, etc. [4] Empagliflozin is the first antidiabetic drug with the new approved indication allowing it to be used for the reduction of cardiovascular mortality risks in patients with type 2 diabetes and comorbid cardiovascular diseases.https://www.med-sovet.pro/jour/article/view/1747type 2 diabetescardiovascular diseasesempagliflozin |
| spellingShingle | M. V. Amosova V. V. Fadeev A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES Медицинский совет type 2 diabetes cardiovascular diseases empagliflozin |
| title | A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES |
| title_full | A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES |
| title_fullStr | A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES |
| title_full_unstemmed | A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES |
| title_short | A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES |
| title_sort | new indication for empagliflozin turning point in the treatment of type 2 diabetes |
| topic | type 2 diabetes cardiovascular diseases empagliflozin |
| url | https://www.med-sovet.pro/jour/article/view/1747 |
| work_keys_str_mv | AT mvamosova anewindicationforempagliflozinturningpointinthetreatmentoftype2diabetes AT vvfadeev anewindicationforempagliflozinturningpointinthetreatmentoftype2diabetes AT mvamosova newindicationforempagliflozinturningpointinthetreatmentoftype2diabetes AT vvfadeev newindicationforempagliflozinturningpointinthetreatmentoftype2diabetes |